Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to improving the lives of patients with genetically defined rare diseases. The company's core mission involves developing small molecules that modulate gene expression to address the underlying causes of gene mis-expression.

Fulcrum's pipeline is centered around its proprietary product engine, which integrates gene regulation, human genetics, cell biology, screening, and computation to identify drug targets. Its lead clinical program is pociredir (formerly FTX-6058), an investigational oral small molecule designed to increase fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). The company also has preclinical programs targeting conditions such as facioscapulohumeral muscular dystrophy (FSHD) and inherited aplastic anemias, including Diamond-Blackfan anemia.

In recent news, Fulcrum Therapeutics reported positive 12-week Phase 1b PIONEER data for pociredir in sickle cell disease, demonstrating robust HbF induction and improvements in markers of hemolysis and anemia. The company plans to initiate a potential registration-enabling trial for pociredir in the second half of 2026, pending feedback from the U.S. Food and Drug Administration (FDA). Additionally, in March 2026, Fulcrum partnered with the MedicAlert Foundation and the Sickle Cell Disease Association of America to enhance emergency care access for individuals with SCD. Alex C. Sapir serves as the President and Chief Executive Officer. As of late 2025, the company maintained a strong financial position with $352.3 million in cash, anticipating a cash runway into at least 2027.